Latest Oncothyreon Inc (ONTY) Headlines
Oncothyreon (ONTY) Jumps: Stock Moves 9.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:46AM CST
Oncothyreon was a big mover last session, as the company saw its shares rise nearly 10% on the day.
Oncothyreon Announces Full Year and Fourth Quarter 2013 Financial Results Conference Call
PR Newswire - Thu Mar 06, 7:00AM CST
Oncothyreon Inc. (Nasdaq: ONTY) today announced that it will conduct a conference call on Thursday, March 13, 2014 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss its full year and fourth quarter 2013 financial results and provide a review of its pipeline of products in development.
Hot Stock: Oncothyreon, Shares Gain 5.4% (ONTY)
Comtex SmarTrend(R) - Wed Mar 05, 12:45PM CST
Oncothyreon (NASDAQ:ONTY) is one of today's best performing low-priced stocks, up 5.4% to $3.41 on 1.3x average daily volume. Thus far today, Oncothyreon has traded 1.2 million shares, vs. average volume of 899,000 shares per day. The stock has outperformed the Dow (5.4% to the Dow's -0.2%) and outperformed the S&P 500 (5.4% to the S&P's 0.0%) during today's trading.
Oncothyreon Inc. (ONTY) in Focus: Stock up 9.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 8:18AM CST
Oncothyreon Inc. was a big mover last session, as the company saw its shares jump a little over 9% on the day.
Oncothyreon to Present at Cowen and Company 34th Annual Health Care Conference
PR Newswire - Wed Feb 26, 7:00AM CST
Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Cowen and Company 34th Annual Health Care Conference in Boston on Wednesday, March 5, 2014 at 9:20 a.m. Eastern.
NewLink's Pancreatic Cancer Vaccine and the Feuerstein-Ratain Rule
at The Street - Wed Feb 26, 6:33AM CST
If history repeats, investor optimism for NewLink's phase III study is misplaced.
Stock to Watch: Oncothyreon Up 8.6% (ONTY)
Comtex SmarTrend(R) - Tue Feb 25, 10:14AM CST
Oncothyreon (NASDAQ:ONTY) is one of today's best performing low-priced stocks, up 8.6% to $3.27 on 1.0x average daily volume. Oncothyreon has traded 944,000 shares thus far today, vs. average volume of 938,000 shares per day. The stock has outperformed the Dow (8.6% to the Dow's 0.0%) and outperformed the S&P 500 (8.6% to the S&P's -0.0%) during today's trading.
Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with TDM-1 in Patients with Metastatic HER2+ Breast Cancer
PR Newswire - Thu Feb 20, 7:00AM CST
Oncothyreon Inc. (NASDAQ: ONTY) and Array BioPharma Inc. (NASDAQ: ARRY) today announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Kadcyla® (ado-trastuzumab emtansine or TDM-1) in patients with metastatic HER2+ breast cancer. ONT-380 is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and being developed by Oncothyreon in collaboration with Array.
Oncothyreon Up 5.8%, Shares Break Through Resistance (ONTY)
Comtex SmarTrend(R) - Tue Feb 11, 11:43AM CST
Oncothyreon (NASDAQ:ONTY) is one of today's best performing low-priced stocks, up 5.8% to $2.75 on 1.2x average daily volume. Thus far today, Oncothyreon has traded 856,000 shares, vs. average volume of 743,000 shares per day. The stock has outperformed the Dow (5.8% to the Dow's 0.9%) and outperformed the S&P 500 (5.8% to the S&P's 0.8%) during today's trading.
Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with Capecitabine and/or Trastuzumab in Patients with Metastatic HER2+ Breast Cancer
PR Newswire - Mon Feb 03, 7:00AM CST
Oncothyreon Inc. (NASDAQ: ONTY) and Array BioPharma Inc. (NASDAQ: ARRY) today announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Xeloda® (capecitabine) and/or Herceptin® (trastuzumab) in patients with metastatic HER2+ breast cancer. ONT-380 is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and being developed by Oncothyreon in collaboration with Array.
Oncothyreon Inc. (ONTY) in Focus: Stock Rises 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 15, 7:44AM CST
Oncothyreon Inc. was a big mover last session, as the company saw its shares rally 9% on the day.
3 Biotech Stocks Under $10 to Watch
at The Street - Wed Jan 15, 6:00AM CST
Keep an eye on these biotech stocks under $10.
Traders Get Bullish on Shares of Oncothyreon, Shares Up 6.4% (ONTY)
Comtex SmarTrend(R) - Tue Jan 14, 10:13AM CST
Oncothyreon (NASDAQ:ONTY) is one of today's best performing low-priced stocks, up 6.4% to $2.01 on 1.4x average daily volume. Oncothyreon has traded 930,000 shares thus far today, vs. average volume of 663,000 shares per day. The stock has outperformed the Dow (6.4% to the Dow's 0.4%) and outperformed the S&P 500 (6.4% to the S&P's 0.6%) during today's trading.
Global Pulmonary Fibrosis Pipeline Review Report - H2 2013 Edition Now Available
M2 - Tue Dec 17, 10:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/cqb72k/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2013" report to their offering. 'Pulmonary Fibrosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis. Scope - A snapshot of the global therapeutic scenario for Pulmonary Fibrosis. - A review of the Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pulmonary Fibrosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Pulmonary Fibrosis Therapeutics Development - Eli Lilly and Company - Lpath, Inc. - Mesoblast Ltd - NicOx SA - Oncothyreon Inc - Pharmaxis Ltd. - Paloma Pharmaceuticals, Inc. - Digna Biotech, S.L. - Aquinox Pharmaceuticals Inc. - Angion Biomedica Corp. - Centocor Ortho Biotech, Inc. - Fibrotech Therapeutics Pty. Ltd. - FCB-Pharmicell Co.,Ltd. - Clarassance, Inc. Drug Profiles - Lpathomab - P-17 - AZX-100 - PX-866 - STNM-04 - P-529 - AQX-1125 - Btx-201 - GR-MD-02 - ICG-001 - CG-1011 - ANG-3298 - C-201 - Galectin-3 Inhibitors - SDP-051 - FT-011 - CT-140 - PDE-4A4 Inhibitors - NCX-466 - MC-1575 - Lungcellgram - CpG Oligonucleotides - PXS-5033-A For more information visit http://www.researchandmarkets.com/research/cqb72k/pulmonary
Stem Cell Therapeutics Appoints Dr. Robert Kirkman to Its Board of Directors
Marketwire - Tue Dec 17, 6:01AM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today announced that industry veteran Dr. Robert L. Kirkman has been appointed to the Company's Board of Directors.
Oncothyreon Inc. (ONTY) in Focus: Stock Up 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 02, 6:44AM CST
Oncothyreon Inc. was a big mover last session, as the company saw its shares rise a little over 5% on the day.
Oncothyreon Reports Third Quarter 2013 Financial Results
PR Newswire - Tue Nov 12, 3:00PM CST
Company to Hold Conference Call at 4:30 p.m. EST Today
Oncothyreon (ONTY) Jumps: Stock Moves 9.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:46AM CST
Oncothyreon was a big mover last session, as the company saw its shares rise nearly 10% on the day.
Oncothyreon Announces Full Year and Fourth Quarter 2013 Financial Results Conference Call
PR Newswire - Thu Mar 06, 7:00AM CST
Oncothyreon Inc. (Nasdaq: ONTY) today announced that it will conduct a conference call on Thursday, March 13, 2014 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss its full year and fourth quarter 2013 financial results and provide a review of its pipeline of products in development.
Hot Stock: Oncothyreon, Shares Gain 5.4% (ONTY)
Comtex SmarTrend(R) - Wed Mar 05, 12:45PM CST
Oncothyreon (NASDAQ:ONTY) is one of today's best performing low-priced stocks, up 5.4% to $3.41 on 1.3x average daily volume. Thus far today, Oncothyreon has traded 1.2 million shares, vs. average volume of 899,000 shares per day. The stock has outperformed the Dow (5.4% to the Dow's -0.2%) and outperformed the S&P 500 (5.4% to the S&P's 0.0%) during today's trading.
Oncothyreon Inc. (ONTY) in Focus: Stock up 9.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 8:18AM CST
Oncothyreon Inc. was a big mover last session, as the company saw its shares jump a little over 9% on the day.
Oncothyreon to Present at Cowen and Company 34th Annual Health Care Conference
PR Newswire - Wed Feb 26, 7:00AM CST
Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Cowen and Company 34th Annual Health Care Conference in Boston on Wednesday, March 5, 2014 at 9:20 a.m. Eastern.
NewLink's Pancreatic Cancer Vaccine and the Feuerstein-Ratain Rule
at The Street - Wed Feb 26, 6:33AM CST
If history repeats, investor optimism for NewLink's phase III study is misplaced.
Stock to Watch: Oncothyreon Up 8.6% (ONTY)
Comtex SmarTrend(R) - Tue Feb 25, 10:14AM CST
Oncothyreon (NASDAQ:ONTY) is one of today's best performing low-priced stocks, up 8.6% to $3.27 on 1.0x average daily volume. Oncothyreon has traded 944,000 shares thus far today, vs. average volume of 938,000 shares per day. The stock has outperformed the Dow (8.6% to the Dow's 0.0%) and outperformed the S&P 500 (8.6% to the S&P's -0.0%) during today's trading.
Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with TDM-1 in Patients with Metastatic HER2+ Breast Cancer
PR Newswire - Thu Feb 20, 7:00AM CST
Oncothyreon Inc. (NASDAQ: ONTY) and Array BioPharma Inc. (NASDAQ: ARRY) today announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Kadcyla® (ado-trastuzumab emtansine or TDM-1) in patients with metastatic HER2+ breast cancer. ONT-380 is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and being developed by Oncothyreon in collaboration with Array.
Oncothyreon Up 5.8%, Shares Break Through Resistance (ONTY)
Comtex SmarTrend(R) - Tue Feb 11, 11:43AM CST
Oncothyreon (NASDAQ:ONTY) is one of today's best performing low-priced stocks, up 5.8% to $2.75 on 1.2x average daily volume. Thus far today, Oncothyreon has traded 856,000 shares, vs. average volume of 743,000 shares per day. The stock has outperformed the Dow (5.8% to the Dow's 0.9%) and outperformed the S&P 500 (5.8% to the S&P's 0.8%) during today's trading.
Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with Capecitabine and/or Trastuzumab in Patients with Metastatic HER2+ Breast Cancer
PR Newswire - Mon Feb 03, 7:00AM CST
Oncothyreon Inc. (NASDAQ: ONTY) and Array BioPharma Inc. (NASDAQ: ARRY) today announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Xeloda® (capecitabine) and/or Herceptin® (trastuzumab) in patients with metastatic HER2+ breast cancer. ONT-380 is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and being developed by Oncothyreon in collaboration with Array.
Oncothyreon Inc. (ONTY) in Focus: Stock Rises 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 15, 7:44AM CST
Oncothyreon Inc. was a big mover last session, as the company saw its shares rally 9% on the day.
3 Biotech Stocks Under $10 to Watch
at The Street - Wed Jan 15, 6:00AM CST
Keep an eye on these biotech stocks under $10.
Traders Get Bullish on Shares of Oncothyreon, Shares Up 6.4% (ONTY)
Comtex SmarTrend(R) - Tue Jan 14, 10:13AM CST
Oncothyreon (NASDAQ:ONTY) is one of today's best performing low-priced stocks, up 6.4% to $2.01 on 1.4x average daily volume. Oncothyreon has traded 930,000 shares thus far today, vs. average volume of 663,000 shares per day. The stock has outperformed the Dow (6.4% to the Dow's 0.4%) and outperformed the S&P 500 (6.4% to the S&P's 0.6%) during today's trading.
Global Pulmonary Fibrosis Pipeline Review Report - H2 2013 Edition Now Available
M2 - Tue Dec 17, 10:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/cqb72k/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2013" report to their offering. 'Pulmonary Fibrosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis. Scope - A snapshot of the global therapeutic scenario for Pulmonary Fibrosis. - A review of the Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pulmonary Fibrosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Pulmonary Fibrosis Therapeutics Development - Eli Lilly and Company - Lpath, Inc. - Mesoblast Ltd - NicOx SA - Oncothyreon Inc - Pharmaxis Ltd. - Paloma Pharmaceuticals, Inc. - Digna Biotech, S.L. - Aquinox Pharmaceuticals Inc. - Angion Biomedica Corp. - Centocor Ortho Biotech, Inc. - Fibrotech Therapeutics Pty. Ltd. - FCB-Pharmicell Co.,Ltd. - Clarassance, Inc. Drug Profiles - Lpathomab - P-17 - AZX-100 - PX-866 - STNM-04 - P-529 - AQX-1125 - Btx-201 - GR-MD-02 - ICG-001 - CG-1011 - ANG-3298 - C-201 - Galectin-3 Inhibitors - SDP-051 - FT-011 - CT-140 - PDE-4A4 Inhibitors - NCX-466 - MC-1575 - Lungcellgram - CpG Oligonucleotides - PXS-5033-A For more information visit http://www.researchandmarkets.com/research/cqb72k/pulmonary
Stem Cell Therapeutics Appoints Dr. Robert Kirkman to Its Board of Directors
Marketwire - Tue Dec 17, 6:01AM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today announced that industry veteran Dr. Robert L. Kirkman has been appointed to the Company's Board of Directors.
Oncothyreon Inc. (ONTY) in Focus: Stock Up 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 02, 6:44AM CST
Oncothyreon Inc. was a big mover last session, as the company saw its shares rise a little over 5% on the day.
Oncothyreon Reports Third Quarter 2013 Financial Results
PR Newswire - Tue Nov 12, 3:00PM CST
Company to Hold Conference Call at 4:30 p.m. EST Today
